While Madison County and the nation are seeing a surge in positive coronavirus cases, the news wasn’t all negative at the weekly COVID-19 briefing at the Huntsville City Council chambers.

The Alabama Department of Public Health announced earlier it received the antibody drug Bamlanivimad to treat virus patients. The Food and Drug Administration gave emergency approval for the drug.

Also, pharmaceutical companies Pfizer and Moderna both said they hoped to ask for emergency authorization for vaccines that were 90 percent effective against the virus in clinical trials.

“The good news is there’s something on the horizon,’’ Huntsville Mayor Tommy Battle said. “But along with that good news we’ve got to stay vigilant, stay ready and continue to do the basics like we have for the last eight months.’’

Those basics are practicing social distance, sanitizing, wearing a mask and avoiding potential unsafe situations.

Crestwood Medical Center CEO Dr. Pam Hudson also urged people to stay safe.

“No matter what anybody says, wear a mask,’’ she said. “And wear it properly.’’

There are 108 hospitalized COVID-19 patients in Crestwood and the Huntsville Hospital system. Of that number 31 are in ICU and 17 are on ventilators.

According to Jeff Birdwell, director of the Huntsville-Madison County Emergency Management Agency, the county had 1,558 confirmed COVID-19 cases in October. About a third of the way through November, there were already more than 700 confirmed cases.

“We are seeing what I would say are significant increases in the first part of the month,’’ he said. “There’s considerable concern there.’’

According to the FDA, Bamlanivimab has been shown in clinical trials to reduce coronavirus-related hospitalizations. The drug is designed for those who have contracted the virus and are at a higher risk for developing more severe symptoms.

The Alabama Department of Public Health is developing a plan to distribute Bamlanivimab to those who may need it.

“The therapeutic is approved for certain patients who have medical criteria that put them at high risk for progressing to severe COVID-19 and/or hospitalization,” said the ADPH in a statement. “This group includes persons who are 65 years of age or older, or who have certain chronic medical conditions. Bamlanivimab is an IV drug treatment and certain requirements must be met in order to use this agent. The department is working with providers to develop a strategic plan for distribution and use of Bamlanivimab.”

Hudson said other therapeutics such as Remdisvir have already helped some COVID-19 patients from requiring hospitalization.

She also said when a vaccine is ready it will be rolled out in three phases. Frontline health care workers will be first to receive the vaccine, followed by high-risk people and then the general public. The hope among health officials is a drug will be ready in late December or January for Phase One, the spring for Phase Two and summer for the final phase.

“It’s not a sprint, it’s a marathon,’’ Hudson said. “This morning a different metaphor came to mind — it’s not a battle, it’s a war.’’